SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 4.99% Passive Stake in 180 Life Sciences Corp.

Sentiment:

Beneficial Ownership Report 4 January 2025 1:08 AM

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 4.99% of 180 Life Sciences Corp.'s common stock as of January 3, 2025.

Capital raiseThe document references a "Securities Purchase Agreement" (SPA) executed on December 27, 2024, between the Issuer and Intracoastal Capital LLC.It notes that 217,000 shares of Common Stock were to be issued to Intracoastal at the closing of the transaction contemplated by the SPA.The filing also mentions that 1,200,000 shares of Common Stock in the aggregate were issued at the closing of the transaction contemplated by the SPA, indicating a broader capital raise event in which Intracoastal participated.

Summary

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G indicating their beneficial ownership in 180 Life Sciences Corp.
As of January 3, 2025, the Reporting Persons collectively beneficially own 165,293 shares of 180 Life Sciences Corp. common stock.
This ownership represents approximately 4.99% of the company's outstanding common stock.
The beneficial ownership consists of 29,800 shares directly held by Intracoastal Capital LLC and 135,493 shares issuable upon the exercise of Intracoastal Warrant 1.
The ownership is capped at 4.99% due to blocker provisions in the warrants (Intracoastal Warrant 1, 2, and 3), which prevent exercise if it would result in beneficial ownership exceeding this threshold.
The filing is made under Rule 13d-1(c), indicating a passive investment purpose, not for changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is largely neutral as a factual disclosure of ownership. However, the presence of a new significant investor, even passive, can be perceived as a slight positive signal of investor interest in the company.

Positives

The disclosure of a significant, albeit passive, stake by an investment entity like Intracoastal Capital LLC may signal investor interest and confidence in 180 Life Sciences Corp.
The presence of blocker provisions ensures the investment remains passive, which may provide stability and avoid potential activist investor conflicts for current management.

Future Outlook

This Schedule 13G filing primarily details historical and current beneficial ownership by the Reporting Persons. It does not contain forward-looking statements or guidance from 180 Life Sciences Corp. regarding its future operations, financial performance, or strategic plans.

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment entity and does not provide specific insights into broader industry trends or competitive dynamics within the life sciences sector. It reflects an investment decision by a specific group of investors in 180 Life Sciences Corp.

Stakeholder Impact

Shareholders: May view the entry of a new significant investor as a positive signal, potentially indicating confidence in the company's future prospects. The passive nature of the investment, capped by blocker provisions, suggests no immediate threat of activist intervention.
Management: The passive nature of the investment, reinforced by blocker provisions, indicates that the investors are not seeking to influence or change control of the company, which may provide stability for current management.

Key Dates

Date	Description
2024-12-27	Date of event requiring the filing; execution of the Securities Purchase Agreement (SPA) with 180 Life Sciences Corp.
2024-12-30	Date the Issuer (180 Life Sciences Corp.) filed a Form 8-K disclosing the Securities Purchase Agreement.
2025-01-03	Date as of which the beneficial ownership is reported and the Schedule 13G was signed and filed.

Keywords

180 Life Sciences Corp., Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Passive Investment, Warrants, Biotechnology, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.